Ping Wang, Ph.D.
Postdoctoral Fellowship, Clinical Chemistry, University of California, San Francisco, CA
Dr. Ping Wang joined the Methodist Hospital as the Medical Director of Clinical Chemistry in 2007 after completing her postdoctoral fellowship in the laboratory of Dr. Alan Wu at the University of California, San Francisco. While a postdoctoral fellow, Dr. Wang studied the pharmacogenomics of the anticoagulant warfarin and created and tested a dosing algorithm for personalized dose management. Natural variation in the genes encoding vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) affect how an individual responds to warfarin. Dr. Wang's algorithm takes into account allelic variation in these two genes, therefore allowing the correct dose to be administered to each individual. Dr. Wang's research also included diagnostic method development using LC-MS/MS and targeted genotyping microarrays. In 2006, Dr. Wang was awarded the prestigious Paul E. Strandjord Young Investigator Award presented by the Academy of Clinical Laboratory Physicians and Scientists for her postdoctoral research.
Dr. Wang's current research focuses on the development of a personalized pharmacogenomics-based algorithm that can be used clinically to achieve fast and accurate tacrolimus dosing in renal transplant recipients. She is also engaged in studying pharmacogenomics of other drugs with low therapeutic indices, with the goal of implementing personalized drug dosing in clinical practice. Analysis and quantitation of drugs and biomarkers using mass spectrometry is another focus of her research.
Pharmacogenomics, personalized medicine, diagnostic methods, mass spectrometry
Shu I, Pina-Oviedo S, Quiroga-Garza G, Meng QH, Wang P. Influence of Vitamin D2 Percentage on Accuracy of 4 Commercial Total 25-Hydroxyvitamin D Assays. Clin Chem. 2013 Jun 12. PMID:23695296
Shu I, Wang P. Simultaneous serum nicotine, cotinine, and trans-3'-hydroxycotinine quantitation with minimal sample volume for tobacco exposure status of solid organ transplant patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jun 1;928:139-45. PMID:23632003
Shu I, Devaraj S, Hanson SE, Little RR, Wang P. Comparison of hemoglobin A1c measurements of samples with elevated fetal hemoglobin by three commercial assays. Clin Chim Acta. 2012 Oct 9;413(19-20):1712-3. PMID:22664058
Wang P, Hudspeth E. Increased body mass index but not common vitamin D receptor, PPARg and cytokine polymorphisms confer predisposition to post-transplant diabetes. Arch Pathol Lab Med. 2011 Dec;135(12):1581-4.
Wang P. Statin dose in Asians: is pharmacogenetics relevant? Pharmacogenomics. 2011 Nov;12(11):1605-15.
Wang P, Mao Y, Razo J, Zhou X, Wong ST, Patel S, Elliott E, Shea E, Wu AH, Gaber AO. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics. 2010 Oct;11(10):1389-402.
Wang P, Molina CP, Maldonado JE, Bernard DW. In utero drugs of abuse exposure testing for newborn twins. J Clin Pathol. 2010 Mar;63(3):259-61.
Wang P, Huang L, Davis JL, Swartzman A, Roth B, Stone J, Wu AH. A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum s-adenosylmethionine in patients infected with human immunodeficiency virus. Clin Chim Acta. 2008 Oct;396(1-2):86-8.